Comment on Burch et al, page 987

Heme, whence come thy carbon building blocks?

Tracey A. Rouault | Eunice Kennedy Shriver National Institute of Child Health and Human Development

In this issue of Blood, Burch et al addressed the challenge of how erythroid cells acquire sufficient carbon for heme synthesis during erythropoiesis.1

Because the citric acid cycle generates succinyl-coenzyme A (succinyl-CoA), which condenses with glycine to form amino-levulinic acid (the first product of heme biosynthesis), it was logical to assume that the carbons of succinyl-CoA were derived from metabolism of glucose through the usual source of succinyl-CoA, the citric acid cycle (see figure). However, siphoning off large amounts of succinyl-CoA from the citric acid cycle to briefly support the synthesis of up to $1.2 \times 10^9$ molecules of heme, each of which incorporates 8 molecules of succinyl-CoA, could severely distort other metabolic pathways that depend on the full activity of the citric acid cycle past the midway point of an α-ketoglutarate formation, the source for succinyl-CoA. By using glucose or glutamine nutrients uniformly labeled with $^{13}$C (a natural stable isotope of carbon that differs in molecular weight from the commonly found carbon-12), the authors concluded that glutamine supplied much more carbon to heme than glucose, whereas a succinate compound downstream of succinyl-CoA in the citric acid cycle contributed almost no carbon. Notably, both glucose and glutamine are abundant in the bloodstream, and either carbon source might theoretically be sufficient. Their discoveries explain how developing erythroid cells can maintain a functional citric acid cycle, even during periods when metabolic activity is heavily skewed toward heme synthesis.

Previously published work showed the importance of glutamine uptake in hematopoietic stem cells, suggesting that blocking glutamine use during differentiation prevented erythroid differentiation and promoted myeloid differentiation, possibly by interfering with nucleoside synthesis.2 To address the role of glutaminolysis, which generates glutamate in the cytosol, the authors treated cells with 6-diazo-5-oxo-L-norleucine, an inhibitor of glutaminolysis, which generates glutamate in the cytosol, the authors treated cells with 6-diazo-5-oxo-L-norleucine, an inhibitor of glutaminolysis and also of many other enzymatic reactions. To more specifically block glutamine synthetase and formation of the α-ketoglutarate precursor glutamate, the authors treated cells with aminoxyacetic acid, a broad-spectrum inhibitor of pyridoxal-5'-phosphate–dependent transaminases. However, many side reactions are still potentially affected by this inhibitor, whereas a specific glutamate synthetase inhibitor, CB839, developed to treat cancers that are thought to depend on glutamine to support anabolic growth, could provide greater specificity in this experimental setting.3 Interestingly, high rates of anemia have not yet been reported to be associated with use of CB839 in experimental trials.

Glutamate enters the mitochondrial matrix through the transporter SLC25A22,
whereupon the enzyme glutamate dehydrogenase converts it to α-ketoglutarate. The enzyme α-ketoglutarate dehydrogenase consists of 3 enzymatic subunits; the E1 subunit is responsible for decarboxylating α-ketoglutarate and converting it to the 4-carbon succinate molecule that enzymatically binds to CoA. The enzyme aminolevulinic acid synthase condenses succinyl-CoA with glycine in the mitochondrial matrix, forming the first heme precursor, aminolevulinic acid (ALA). ALA is exported to the cytosol, where several enzymes gradually build the porphyrin ring, which reenters the mitochondria to undergo the 2 final heme biosynthetic steps, which include insertion of iron at the center of the porphyrin ring. Because the pathway from exogenous glutamine to succinate CoA needs large amounts of the enzyme α-ketoglutarate dehydrogenase to directly glutamate into succinyl-CoA, the authors checked levels of the E1 subunit of α-ketoglutarate, and they found that levels increased about fourfold during differentiation, indicating that the cell was able to regulate and remodel important metabolic steps to maintain metabolic functions of the full citric acid cycle despite diversion of large amounts of succinyl-CoA into heme synthesis.

Similar to other studies that alter a widely accepted paradigm, the article by Burch et al raises several questions that merit further study. How does the erythroid cell remodel expression of α-ketoglutarate dehydrogenase to more efficiently funnel succinyl-CoA into heme biosynthesis? Are levels of the plasma membrane glutamine importer, the mitochondrial glutamate importer, or the plasma membrane and mitochondrial glycine importers also increased in heme-synthesizing erythroid cells? The authors conclude that glutamine plays another undefined role in promoting early erythropoiesis that extends beyond its role in serving as a precursor to heme and nucleotide synthesis. Notably, enzymatic activities of aconitase and isocitrate dehydrogenase were high in erythroid cells, which is interesting because these enzymes are important in a process known as reductive carboxylation, in which α-ketoglutarate is carboxylated by isocitrate dehydrogenase and converted to citrate by aconitase. A mitochondrial citrate exporter could export a precursor of fatty acid synthesis to the cytosol, which could alter metabolism in other yet unrecognized ways.

The heme biosynthetic pathway has been an unending source of wonder for decades.

Here, the article by Burch et al reminds us that much remains to be learned, and many assumptions may be overturned by experimental interrogation in the future. Newer methodologies such as metabolomics have opened the way to fresh insights into the process of heme biosynthesis.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

DOI 10.1182/blood-2018-07-844215

CLINICAL TRIALS AND OBSERVATIONS

Comment on Svoboda et al, page 1022

CART19 in Hodgkin lymphoma: are we driving the right model?

Catherine S. Diefenbach | Perlmutter Cancer Center at New York University Langone Health

In this issue of Blood, Svoboda and colleagues describe, for the first time, the safety, feasibility, and activity of a nonviral RNA chimeric antigen receptor (CAR) modified T-cell (CART) construct targeting CD19 in relapsed Hodgkin lymphoma (HL).1

CART therapy has demonstrated significant activity in relapsed diffuse large B-cell lymphoma and acute lymphocytic leukemia (ALL), resulting in approval by the US Food and Drug Administration in both of these diseases. As CARs move from bench to bedside in other malignancies, there are several key questions that remain. In relapsed HL, there are important benchmarks that an investigational new agent must meet. Is the spectrum of toxicity comparable to that of existing therapies? Can it be safely delivered or are there significant or unusual toxicities? If it is more toxic, does this therapy have significantly greater efficacy than existing therapies? How does response rate and durability compare with those of existing therapies? Does this therapy possess a novel mechanism that expands on therapeutic options for patients with relapsed HL?

These nonmalignant inflammatory cells produce soluble and membrane-bound molecules that promote tumor cell growth, evasion of self-immunity, and survival.2 The T cells in the HL microenvironment demonstrate anergy to recall antigen when stimulated, and an association between high numbers of CD68+ tumor-associated macrophages and shortened survival has been described.3 This biology suggests that CART approaches could be uniquely potent and toxic. A review of the current literature reveals 2 studies that report CD30 CARs in HL using viral vectors, which do not report any unusual or excessive toxicity.4,5 suggesting that in small numbers of patients with CD30-targeted CARs, the unique HL tumor microenvironment (TME) does not lead to unusual or excessive toxicity. In this context, with this data, it is unclear why the investigators chose their approach of transfecting T cells with messenger RNA using electroporation in contrast to a viral vector. This approach leads to a transient expression of the CAR with the intention...